INCY Latest Headlines

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY), Fulcrum Therapeutics (FULC) and Arcellx Inc (ACLX)

at www.tipranks.com (Mon, 8-Dec 8:20 AM)

Incyte (INCY) Gets a Hold from Evercore ISI

at www.tipranks.com (Mon, 8-Dec 8:16 AM)

Guggenheim Remains a Buy on Incyte (INCY)

at www.tipranks.com (Mon, 8-Dec 8:15 AM)

TD Cowen Sticks to Its Buy Rating for Incyte (INCY)

at www.tipranks.com (Mon, 8-Dec 6:56 AM)

Incyte’s Mutant CALR Antibody Shows Promise but Faces Uncertainties: Hold Rating Issued

at www.tipranks.com (Mon, 8-Dec 6:39 AM)

Incyte’s INCA033989: Promising Myelofibrosis Treatment Drives Buy Rating

at www.tipranks.com (Mon, 8-Dec 6:39 AM)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Immatics (IMTX), Incyte (INCY) and Cogent Biosciences (COGT)

at www.tipranks.com (Mon, 8-Dec 5:50 AM)

Incyte (INCY) Receives a Buy from Barclays

at www.tipranks.com (Mon, 8-Dec 3:45 AM)

FDA fast-tracks Incyte drug for rare blood cancer

at seekingalpha.com (Sun, 7-Dec 10:31 AM)

Incyte Secures $910 Million Option on Prelude’s JAK2V617F JH2 Inhibitor Program Targeting Myeloproliferative Neoplasms

Market Chameleon (Tue, 4-Nov 7:52 AM)

Incyte Lifts Revenue Guidance for 2025 Amid Double-Digit Product Growth and Focused R&D Investment

Market Chameleon (Tue, 28-Oct 7:21 AM)

Baricitinib Delivers High Rates of Hair Regrowth in Adolescents With Severe Alopecia—Largest Pediatric Study Shows Promising One-Year Data

Market Chameleon (Fri, 24-Oct 8:43 AM)